ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Aethlon Medical Inc

Aethlon Medical Inc (AEMD)

0.42
0.01
(2.44%)
Closed May 25 4:00PM
0.42
0.00
(0.00%)
After Hours: 6:37PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.42
Bid
0.4001
Ask
0.42
Volume
602,879
0.37091 Day's Range 0.425
0.3704 52 Week Range 5.00
Market Cap
Previous Close
0.41
Open
0.4125
Last Trade
95
@
0.4199
Last Trade Time
Financial Volume
$ 241,971
VWAP
0.40136
Average Volume (3m)
648,064
Shares Outstanding
2,620,399
Dividend Yield
-
PE Ratio
-0.09
Earnings Per Share (EPS)
-4.59
Revenue
574k
Net Profit
-12.03M

About Aethlon Medical Inc

Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which... Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which signifies diagnostic business activities. It is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and to eliminate life-threatening viruses from the circulatory system. The company generates revenue from Aethlon segment. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Carson City, Nevada, USA
Founded
1970
Aethlon Medical Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker AEMD. The last closing price for Aethlon Medical was $0.41. Over the last year, Aethlon Medical shares have traded in a share price range of $ 0.3704 to $ 5.00.

Aethlon Medical currently has 2,620,399 shares outstanding. The market capitalization of Aethlon Medical is $1.10 million. Aethlon Medical has a price to earnings ratio (PE ratio) of -0.09.

AEMD Latest News

Aethlon Medical Announces Pricing of $4.7 Million Public Offering

Aethlon Medical Announces Pricing of $4.7 Million Public Offering PR Newswire SAN DIEGO, May 15, 2024 SAN DIEGO, May 15, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical...

Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma

Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma PR Newswire SAN DIEGO, May 10, 2024...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.420.47180.370918380060.4193183CS
4-1.08-721.51.790.370418946490.86664183CS
12-1.19-73.91304347831.611.850.37046480640.87365809CS
26-1.25-74.85029940121.672.34990.37043146690.90452001CS
52-2.754-86.76748582233.17450.37042499531.93368399CS
156-17.38-97.640449438217.8124.90.3704131711645.08984428CS
260-3.082-88.00685322673.502124.90.3704119628837.68360818CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

AEMD Discussion

View Posts
Disquisition Disquisition 4 days ago
DUMPED back to low .40zzz after it almost broke out…
👍️0
Termite7 Termite7 6 days ago
Is this one of those 100-baggers? .......Thanks!!!
👍️0
The GidDy uP Kid The GidDy uP Kid 1 week ago
AEMD… 3 daily gap dowNs, way below the lower keltner line here… GidDy uP AEMD
https://schrts.co/TxGGNVAi
👍️0
The GidDy uP Kid The GidDy uP Kid 1 week ago
....
👍️0
The GidDy uP Kid The GidDy uP Kid 1 week ago
...
👍️0
The GidDy uP Kid The GidDy uP Kid 1 week ago
AEMD creeping uP after hours… Still Cheapies…
👍️0
Nickolas40 Nickolas40 1 week ago
Even lower now.
👍️0
Monksdream Monksdream 2 weeks ago
AEMD new 52 low
👍️0
Monksdream Monksdream 2 weeks ago
Will it grow legs after 9:30
Most med techs don’t
👍️0
Awl416 Awl416 2 weeks ago
Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
👍️0
Monksdream Monksdream 4 weeks ago
AEMD new 52 week low
👍️0
mick mick 5 months ago
https://www.otcmarkets.com/stock/AEMD
👍️0
mick mick 5 months ago
https://www.otcmarkets.com/stock/AEMD
👍️0
mick mick 7 months ago
https://www.otcmarkets.com/stock/AEMD
👍️0
Monksdream Monksdream 7 months ago
AEMD new 52 week low
👍️0
Monksdream Monksdream 7 months ago
AEMD new 52 week low
👍️0
mick mick 8 months ago
https://www.otcmarkets.com/stock/AEMD
👍️0
mick mick 9 months ago
HAS AMED R/S YET ?????
👍️0
mick mick 9 months ago
AEMD
Aethlon Medical Inc
0.331
-0.0156 (-4.50%)
Volume: 77,709
Day Range: 0.3213 - 0.3466
Last Trade Time: 7:52:36 PM EDT
👍️0
twogreen2c twogreen2c 10 months ago
Ahhh the ole R/S to purge the investors. I kissed this one goodbye a long time ago. This will be my 3rd R/S. Nothing left of this garbage I've had stinkin up my portfolio since 2014. This is what they do in pennyland. Per the proxy: Reverse stock split of our common stock at a ratio in the range of 1-for-8 to 1-for-12, with such ratio to be determined in the discretion of our Board of Directors and with such reverse stock split to be effected at such time and date as determined by our Board of Directors in its sole discretion.
👍️0
mick mick 10 months ago
AEMD
Aethlon Medical Inc
0.436
0.0016 (0.37%)
Volume: 87,927
Day Range: 0.4201 - 0.4599
Bid: 0.4359
Ask: 0.4499
Last Trade Time: 7:30:44 PM EDT
Total Trades: 258
👍️0
Monroe1 Monroe1 10 months ago
Gathering steam. Yes, $AEMD$
👍️0
mick mick 10 months ago
yes AEMD
Aethlon Medical Inc
0.4344
-0.0159 (-3.53%)
Volume: 217,584
Day Range: 0.432 - 0.46
Bid: 0.4562
Ask: 0.458
Last Trade Time: 4:36:56 PM EDT
Total Trades: 384
👍️0
Monroe1 Monroe1 11 months ago
Stairway to heaven!!
👍️0
mick mick 11 months ago
AEMD
Aethlon Medical Inc
0.418
-0.007 (-1.65%)
Volume: 761,142
Day Range: 0.40 - 0.4375
Last Trade Time: 7:54:26 PM EDT
👍️0
mick mick 11 months ago
AEMD
Aethlon Medical Inc
0.418
-0.007 (-1.65%)
Volume: 761,142
Day Range: 0.40 - 0.4375
Bid: 0.417
Ask: 0.4349
Last Trade Time: 7:54:26 PM EDT
Total Trades: 1,490
👍️0
Monroe1 Monroe1 11 months ago
close .425 according to my fidlelity.
bought a few more a tad higher than close. Nice volume. Glad though I added a few days ago as well.
👍️0
mick mick 11 months ago
yes, creeping <> AEMD
Aethlon Medical Inc
0.4101
0.0701 (20.62%)
Volume: 8,100,795
Day Range: 0.38 - 0.50
Bid: 0.4101
Ask: 0.417
Last Trade Time: 7:58:04 PM EDT
Total Trades: 10,320
👍️0
Monroe1 Monroe1 11 months ago
Potential here is quite large and transformative in more than a few areas. fda seems quite cooperative now too which is quite unusual.
👍️0
mick mick 11 months ago
Jun-30-23 12:42PM
Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2023 Earnings Call Transcript
(Insider Monkey)
-9.82%
Jun-28-23 04:15PM
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
(PR Newswire)
+7.85%
Jun-22-23 08:01AM
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
(PR Newswire)
Jun-21-23 08:01AM
Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation
(PR Newswire)
Jun-14-23 08:01AM
Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest
(PR Newswire)
09:13AM
Loading…
Jun-08-23 09:13AM
AEMD: Maximizing R&D Spending to Facilitate Clinical Efforts, Advance Hemopurifier
(Zacks Small Cap Research)
Jun-01-23 03:51PM
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
(PR Newswire)
👍️0
mick mick 11 months ago
https://finance.yahoo.com/news/aethlon-medical-inc-nasdaq-aemd-164226202.html
👍️0
mick mick 11 months ago
https://finance.yahoo.com/news/aethlon-medical-inc-nasdaq-aemd-164226202.html
👍️0
mick mick 11 months ago
Book/sh 0.75
👍️0
mick mick 11 months ago
Market Cap 8.28M
👍️0
mick mick 11 months ago
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023 • PR Newswire (US) • 06/22/2023 12:01:00 PM
👍️0
mick mick 11 months ago
Short Interest 0.10M
👍️0
mick mick 11 months ago
Shs Float 22.70M
👍️0
mick mick 11 months ago
Shs Outstand 22.95M
👍️0
mick mick 11 months ago
https://finviz.com/quote.ashx?t=AEMD&ty=c&ta=1&p=d
👍️0
mick mick 11 months ago
NEUTRAL <> interesting yet ????? $AEMD 06-18-2020 Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
PR Newswire PR Newswire•June 18, 2020
Allows for enrollment of up to 40 subjects in up to 20 centers

https://finance.yahoo.com/news/aethlon-announces-fda-approval-ide-131900535.html

SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a

supplement to the Company's existing Investigational Device Exemption (IDE) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.

The feasibility study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19,

be admitted to an intensive care unit (ICU) and will have acute lung injury and/or severe or life threatening disease among other criteria.

The Hemopurifier has previously been tested in patients with hepatitis
C virus (HCV) infection and in one patient with Ebola virus infection.

A laboratory version of the Hemopurifier has also been shown to clear multiple other viruses in vitro including a model version of the
Middle Eastern Respiratory Syndrome (MERS) virus which is a
coronavirus from the same family as the SARS-CoV-2 virus that causes COVID-19.

Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon, stated,
"We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19.

We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease."

The Hemopurifier is an FDA designated "Breakthrough Device" for the treatment of life-threatening viruses that are not addressed with approved therapies.

The Hemopurifier also holds a Breakthrough Device designation for the treatment of individuals with advanced or metastatic cancer who are

either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.

About Aethlon Medical, Inc.
Aethlon Medical, Inc. is focused on addressing unmet needs in global health.

The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections.

Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on
the discovery of exosomal biomarkers to diagnose and monitor cancer
and neurological disease progression. Additional information can be found online at
http://www.AethlonMedical.com and http://www.ExosomeSciences.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," "appear" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, Aethlon Medical, Inc.'s (the Company) ability to enroll patients and to successfully complete the Early Feasibility Studies in viral diseases and cancer and achieve the endpoints for the study or any future studies with its Hemopurifier or to successfully develop and commercialize the Hemopurifier. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Continue reading

http://ih.advfn.com/stock-market/NASDAQ/aethlon-medical-AEMD/stock-news/82687431/aethlon-announces-fda-approval-of-ide-supplement


Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com

Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650

Cision
Cision
More
View original content:http://www.prnewswire.com/news-releases/aethlon-announces-fda-approval-of-ide-supplement--for-covid-19-patients-301079557.html

👍️0
mick mick 11 months ago
NEUTRAL <> interesting yet ????? $AEMD 06-18-2020 Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
PR Newswire PR Newswire•June 18, 2020
Allows for enrollment of up to 40 subjects in up to 20 centers

https://finance.yahoo.com/news/aethlon-announces-fda-approval-ide-131900535.html

SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a

supplement to the Company's existing Investigational Device Exemption (IDE) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.

The feasibility study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19,

be admitted to an intensive care unit (ICU) and will have acute lung injury and/or severe or life threatening disease among other criteria.

The Hemopurifier has previously been tested in patients with hepatitis
C virus (HCV) infection and in one patient with Ebola virus infection.

A laboratory version of the Hemopurifier has also been shown to clear multiple other viruses in vitro including a model version of the
Middle Eastern Respiratory Syndrome (MERS) virus which is a
coronavirus from the same family as the SARS-CoV-2 virus that causes COVID-19.

Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon, stated,
"We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19.

We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease."

The Hemopurifier is an FDA designated "Breakthrough Device" for the treatment of life-threatening viruses that are not addressed with approved therapies.

The Hemopurifier also holds a Breakthrough Device designation for the treatment of individuals with advanced or metastatic cancer who are

either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.

About Aethlon Medical, Inc.
Aethlon Medical, Inc. is focused on addressing unmet needs in global health.

The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections.

Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on
the discovery of exosomal biomarkers to diagnose and monitor cancer
and neurological disease progression. Additional information can be found online at
http://www.AethlonMedical.com and http://www.ExosomeSciences.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," "appear" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, Aethlon Medical, Inc.'s (the Company) ability to enroll patients and to successfully complete the Early Feasibility Studies in viral diseases and cancer and achieve the endpoints for the study or any future studies with its Hemopurifier or to successfully develop and commercialize the Hemopurifier. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Continue reading

http://ih.advfn.com/stock-market/NASDAQ/aethlon-medical-AEMD/stock-news/82687431/aethlon-announces-fda-approval-of-ide-supplement


Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com

Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650

Cision
Cision
More
View original content:http://www.prnewswire.com/news-releases/aethlon-announces-fda-approval-of-ide-supplement--for-covid-19-patients-301079557.html

👍️0
mick mick 11 months ago
good rev reading
👍️0
mick mick 11 months ago
good rev reading
👍️0
Monroe1 Monroe1 11 months ago
Things are getting much brighter here. 14 Million in the bank and ........


Aethlon Medical Q4 EPS $(0.11) Up From $(0.25) YoY, Sales $574.25K Up From $13.12K YoY

BENZINGA

4:37 PM ET 06/28/2023
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.11) per share. This is a 56 percent increase over losses of $(0.25) per share from the same period last year. The company reported $574.25 thousand in sales this quarter. This is a 4.28K percent increase over sales of $13.12 thousand the same period last year.
👍️ 1
mick mick 11 months ago
AEMD
Aethlon Medical Inc
0.3772
-0.0012 (-0.32%)
Volume: 205,819
Day Range: 0.3728 - 0.38
Last Trade Time: 7:35:14 PM EDT
👍️0
mick mick 11 months ago
MAYBE CHANCE FER BIG ONE ????? $AMED
👍️0
mick mick 12 months ago
AEMD
Aethlon Medical Inc
0.3092
0.0136 (4.60%)
Volume: 133,425
Day Range: 0.300001 - 0.32
Last Trade Time: 7:10:51 PM EDT
👍️0
mick mick 12 months ago
AEMD
Aethlon Medical Inc
0.3092
0.0136 (4.60%)
Volume: 133,425
Day Range: 0.300001 - 0.32
Last Trade Time: 7:10:51 PM EDT
👍️0
mick mick 1 year ago
AEMD
Aethlon Medical Inc
0.38
-0.0168 (-4.23%)
Volume: 479,255
Day Range: 0.3601 - 0.40
Last Trade Time: 7:59:20 PM EDT
👍️0
Mt. Blanc Mt. Blanc 1 year ago
Choo choo play as they want the chase.

AEMD

mb
👍️0

Your Recent History

Delayed Upgrade Clock